Glycopyrrolate/formoterol fumarate vs Olodaterol/tiotropium bromide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanisms: Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere
Marketed by AstraZeneca
NCT03324607 · Phase 2/3 · completed
The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.
Reported efficacy
Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2); Barrier Uptake. (2 weeks); Red Blood Cell (RBC) Uptake (2 weeks): Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2): Treatment — Baseline: 57.8 percentage of total ventilation (Standard Deviation 8.4); Week 2: 52.5 percentage of total ventilation (Standard Deviation 10.6) (mixed)
Result source: NCT03324607
Olodaterol/tiotropium bromide
Marketed by Boehringer Ingelheim
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Glycopyrrolate/formoterol fumarate | Olodaterol/tiotropium bromide |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | —Not reported |
| Trough FEV1, change | —Not reported | —Not reported |
| SGRQ total, change | —Not reported | —Not reported |
| TDI focal score | —Not reported | —Not reported |
Moderate or severe exacerbations, annualised rate
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Olodaterol/tiotropium bromide
- —Not reported
Trough FEV1, change
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Olodaterol/tiotropium bromide
- —Not reported
SGRQ total, change
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Olodaterol/tiotropium bromide
- —Not reported
TDI focal score
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Olodaterol/tiotropium bromide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Olodaterol/tiotropium bromide: registry results are on file for Chronic Obstructive Pulmonary Disease, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Glycopyrrolate/formoterol fumarate: 2 of 4 rows · Olodaterol/tiotropium bromide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Glycopyrrolate/formoterol fumarate |
|---|---|
| Dropout rate | 0%a NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result— NCT03081156 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result— NCT03081156 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 0%a NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result12.5% NCT03081156 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | — |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Glycopyrrolate/formoterol fumarate
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrrolate/formoterol fumarate's landscape · Olodaterol/tiotropium bromide's landscape